$19m · Series B · Healthtech · Neuchâtel, Switzerland
Neuchâtel-based Hilo, the blood-pressure technology brand developed by Aktiia, has raised a $19m Series B extension led by Dell Family Office, with continued support from existing backers. The company says the financing takes its total funding above $119m. It announced the extension on 21 July alongside the US launch of Hilo Core.
Blood-pressure data between cuff readings
Hilo Core combines a wrist-worn band, a mobile app and an FDA-cleared upper-arm cuff. The band uses optical photoplethysmographic signals and algorithms to estimate blood-pressure patterns, while periodic measurements from the connected cuff calibrate the system. Hilo says this produces around 30–35 readings a day, including overnight, and places them alongside sleep, activity and heart-rate data.
The product is designed to replace isolated snapshots with a longer view of how blood pressure changes through daily life. That makes the commercial proposition different from selling a cuff alone: the hardware starts the relationship, while the $149.99 annual subscription keeps the app, trend summaries and product experience recurring. The US package launched through Hilo.com and Amazon at $89.99 for the hardware, bringing the first-year total to $239.98.
The US launch is the next commercial test
The regulatory boundary matters. The connected cuff is FDA-cleared, but Hilo Core itself is marketed as a wellness product, not an FDA-cleared medical device, and its wrist-generated estimates are not intended to diagnose hypertension or guide treatment. Hilo therefore has to make longitudinal data useful without encouraging users to treat wellness insights as a substitute for clinical measurements.
The company says its underlying technology has been validated in eight clinical studies and used by more than 200,000 people globally. Those figures give Hilo a larger real-world base than a new wearable launch, but the US model still has to prove that consumers will pay for continuing blood-pressure context rather than a one-off device.
According to Tech Funding News, the extension will support US expansion, product development and hiring. The capital arrives as distribution opens, so the useful milestones are now commercial and regulatory: subscription retention, sustained use of the cuff-and-band workflow, and evidence that the product can expand beyond general wellness without overstating what it is cleared to do.
Sources checked:
Hilo / PR Newswire · Hilo company post · MobiHealthNews · Tech Funding News · Hilo company terms · Tech.eu Funding Explorer
